Страна: Израиль
Язык: английский
Источник: Ministry of Health
FACTOR IX
KAMADA LTD, ISRAEL
B02BD01
POWDER FOR SOLUTION FOR INJECTION
FACTOR IX 1000 IU/VIAL
I.V
Required
BIO PRODUCTS LABORATORY LIMITED, UK
COAGULATION FACTOR IX, II, VII AND X IN COMBINATION
COAGULATION FACTOR IX, II, VII AND X IN COMBINATION
Treatment and prophylaxis of bleeding in patients with haemophilia B ( congenital factor IX deficiency).
2021-07-31
_ _ _ _ 1 _ _ _ _ _ _ _ _ R R E E P P L L E E N N I I N N E E - - V V F F 1. NAME OF THE MEDICINAL PRODUCT Replenine-VF 500, powder for solution for injection Replenine-VF 1000, powder for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Replenine-VF contains high purity human coagulation factor IX. 500 IU Each vial contains nominally 500 IU human coagulation factor IX. Replenine-VF contains approximately 50 IU/ml of human coagulation factor IX after reconstitution at full volume. 1000 IU Each vial contains nominally 1000 IU human coagulation factor IX. Replenine-VF contains approximately 50 IU/ml of human coagulation factor IX after reconstitution at full volume. One ml of Replenine-VF contains approximately 100 IU human coagulation factor IX after reconstitution at half volume (see section 6.6). The potency (IU) is determined using the European Pharmacopoeia one stage clotting test. The specific activity of Replenine-VF is approximately 100 IU/mg protein. Produced from the plasma of human donors. Excipient with known effect: This medicinal product contains up to 83 mg sodium per vial, equivalent to 4% of the WHO recommended maximum daily intake of 2 g sodium for an adult. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for solution for injection. Powder: White or slightly coloured powder. Solvent: Clear colourless liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment should be under the supervision of a physician experienced in the treatment of haemophilia. _ _ _ _ 2 _ _ _ _ _ _ _ _ _Treatment monitoring _ During the course of treatment, appropriate determination of factor IX levels is advised to guide the dose to be administered and the frequency of repeated infusions. Individual patients may vary in their response to factor IX, demonstrating different half-lives and recoveries. Dose based Прочитать полный документ